CLLS
Cellectis S.A.
NASDAQ · Healthcare · Biotechnology · FR
$3.24
−2.41%Jun 25, 2026, 20:30 UTC
Cellectis held its shareholders general meeting on June 25, 2026, where resolutions 1 through 29 were adopted and resolution 30 was rejected.
Source:Jun 9, 2026, 20:30 UTC
The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to Cellectis' lasme-cel for relapsed or refractory B-cell acute lymphoblastic leukemia.
Source: